Natera sells blood tests that read DNA to screen pregnancies, detect cancer recurrence, and monitor organ transplants—think of it as a genetic detective for hospitals and labs.
Money comes from selling these molecular tests, with gross margins around 65% on USD 2.31B revenue in 2025. The business is still unprofitable, posting a net loss of USD 0.21B that year.
Natera's proprietary algorithms and bioinformatics, plus partnerships with BGI Genomics and Foundation Medicine, create switching costs for labs. However, competitors like Illumina and Guardant Health are pushing into similar ctDNA and prenatal testing, erodin
Hold (sector percentile 49) — value C, growth B+, profitability B-, momentum B+, revisions B-. Updated daily, sector-relative, identical for every user.
Key events, in time order
Latitude used in Kupando Phase 1 to track ctDNA and characterize response to KUP-101
Top holding at $865M, 3.19M shares, signaling strong conviction
Shares surge over 20% post-earnings, up 40% YTD, drawing institutional attention
Q2 loss of $0.47/share improves from year-ago $0.74; shares surge over 20% to record high
Cetera cut stake by 9.5%, while Druckenmiller's 18% position draws attention, extending institutional activity narrative
Submission targets muscle-invasive bladder cancer, a key regulatory step for Signatera in Japan
Two funds raised NTRA stakes last quarter, extending the recent institutional repositioning theme without new directional facts.
Prospective multicenter study shows Signatera outperforms AMERK, adding clinical evidence for the product.
Amova reduced by 10.1%, Fifth Third increased by 3373.1%, CalPERS cut by 23.4%, showing institutional divergence.
Billionaire Druckenmiller's top holding in Natera highlights its investment appeal.
Finalized MolDx LCD expands coverage for Prospera tests, impacting market access.
Duquesne's NTRA stake at 18.1% confirms prior top-position report
None yet
None yet
Natera is mentioned as one of IBD's Top 50 Stocks, indicating positive recognition for its performance and potential.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
